This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synta Provides Clinical Update And Reports Third Quarter 2012 Financial Results

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the third quarter ended September 30, 2012 and provided clinical program updates regarding its lead oncology drug candidate, ganetespib, a potent and selective Hsp90 inhibitor.

“Clinical development of ganetespib has progressed exceptionally well this year, culminating with the recent presentation of positive interim results from the first stage of our 800-patient Phase 2b/3 randomized GALAXY program in non-small cell lung cancer,” said Safi Bahcall, Ph.D., President and CEO. “These encouraging results in combination with docetaxel, together with the previously reported promising results with ganetespib monotherapy in certain targeted patient populations, create exciting opportunities for multiple paths to registration and a unique product profile. We have been pleased with the strong support for this program in the medical oncology community, reflected in increasing rates of enrollment across all our trials and a growing number of third-party supported programs. We are looking forward to upcoming results from GALAXY and our other programs, and to realizing our goal of creating a new treatment option for cancer patients.”

Ganetespib is currently being evaluated in over 20 clinical studies. In addition to the activity observed in the GALAXY combination therapy trial, objective responses or durable anti-tumor activity have been observed with ganetespib monotherapy in patients with lung cancer, breast cancer, gastric cancer, colorectal cancer, renal cancer, and melanoma. The safety profile of ganetespib has been favorable in over 600 patients treated to date, with transient, mild or moderate diarrhea as the most common adverse event reported.

Key accomplishments in the third quarter of 2012:

1. At the 2012 Congress of the European Society for Medical Oncology (ESMO), investigators reported results from the second interim efficacy analysis of the Phase 2b portion of the GALAXY trial. There were 172 adenocarcinoma patients in the clinical database at the time of the September 10 cutoff for this analysis.

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs